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Introduction: 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs.   
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to elicit 
those anti-cancer therapies which might be associated with either a considerable impact on financial 
resources or a substantial health benefit.  
For the 18
th
 prioritisation (March 2014), 12 were filtered out of 192 identified and were sent to 
prioritisation. Of these, 7 drugs were ranked as ‘highly relevant’ by the expert panel, 4 as ‘relevant’ and 
one as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for example, abstracts of 
phase III studies and licensing status is contained in this document.  
An overview on all drugs sent to prioritisation and the summary judgements of the expert panel are 
provided in the following table.  
No Filtered Drugs - 18
th
 prioritisation 1
st
 quarter 2014 Overall category 
1.  Bevacizumab (Avastin®) for the maintenance therapy of advanced non-
small-cell lung cancer  
Relevant 
2.  Erlotinib (Tarceva®) for the first-line therapy of stage IIIB/IV non-small-cell 
lung cancer  
Highly relevant  
3.  Nintedanib (Vargatef®) for the second-line therapy of  advanced or 
recurrent non-small-cell lung cancer  
Highly relevant 
4.  Bevacizumab (Avastin®) as maintenance therapy for patients with 
advanced colorectal carcinoma 
Highly relevant 
5.  Obinutuzumab afutuzumab (Gazyva®) as first line therapy for chronic 
lymphocytic leukaemia  
Highly relevant  
6.  Idelalisib (GS-1101) for relapsed chronic lymphocytic leukaemia Highly relevant  
7.  Docetaxel (Taxotere®, Docefim) for the second-line therapy of  patients 
with relapsed oesophago-gastric adenocarcinoma 
Not relevant 
8.  Ramucirumab (IMC-1121B) in patients with metastatic gastric 
adenocarcinoma, refractory to or progressive after first-line therapy with 
platinum and fluoropyrimidine 
Relevant  
9.  Cabozantinib (Cometriq®) in patients with unresectable, locally advanced 
or metastatic medullary thyroid cancer (MTC) 
Highly relevant  
10.  Sorafenib (Nexavar®) in patients with advanced/metastatic thyroid cancer 
refractory to radioactive iodine treatment 
Relevant  
11.  Axitinib (Inlyta®) for the first-line treatment of metastatic renal cell cancer Relevant  
12.  Ibrutinib (Imbruvica®) in patients with relapsed or refractory mantle cell 
lymphoma 
Highly relevant  
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Lung Cancer 
Erlotinib (Tarceva®) for the first-line therapy of stage IIIB/IV Non-
small cell lung cancer 
Drug description:  An oral inhibitor of epidermal growth factor receptor tyrosine kinase. 
Incidence in Austria: 4,200 patients, about 85% of all lung cancers belong to NSCLC 
EMA/FDA licensing: -/- 
Phase III results:  
 
Wu et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage 
non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. The Lancet Oncology. 
2013; 14(8):777-86. 
 
Background 
The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated 
chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with 
advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient 
population. 
 
Methods 
In this phase 3 trial, patients with untreated stage IIIB/IV non-small-cell lung cancer were randomly 
assigned in a 1:1 ratio by use of an interactive internet response system with minimisation algorithm 
(stratified by disease stage, tumour histology, smoking status, and chemotherapy regimen) to receive 
six cycles of gemcitabine (1250 mg/m² on days 1 and 8, intravenously) plus platinum (carboplatin 5 × 
area under the curve or cisplatin 75 mg/m² on day 1, intravenously) with intercalated erlotinib (150 
mg/day on days 15–28, orally; chemotherapy plus erlotinib) or placebo orally (chemotherapy plus 
placebo) every 4 weeks. With the exception of an independent group responsible for monitoring data 
and safety monitoring board, everyone outside the interactive internet response system company was 
masked to treatment allocation. Patients continued to receive erlotinib or placebo until progression or 
unacceptable toxicity or death, and all patients in the placebo group were off ered second-line erlotinib 
at the time of progression. The primary endpoint was PFS in the intention-to-treat population. 
 
Results 
From April 29, 2009, to Sept 9, 2010, 451 patients were randomly assigned to chemotherapy plus 
erlotinib (n=226) or chemotherapy plus placebo (n=225). PFS was significantly prolonged with 
chemotherapy plus erlotinib versus chemotherapy plus placebo (median PFS 7·6 months [95% CI 
7·2–8·3], vs 6·0 months [5·6–7·1], hazard ratio [HR] 0·57 [0·47–0·69]; p<0·0001). Median overall 
survival for patients in the chemotherapy plus erlotinib and chemotherapy plus placebo groups was 
18·3 months (16·3–20·8) and 15·2 months (12·7–17·5), respectively (HR 0·79 [0·64–0·99]; p=0·0420). 
Treatment benefit was noted only in patients with an activating EGFR gene mutation (median PFS 
16·8 months [12·9–20·4] vs 6·9 months [5·3–7·6], HR 0·25 [0·16–0·39]; p<0·0001; median overall 
survival 31·4 months [22·2–undefi ned], vs 20·6 months [14·2–26·9], HR 0·48 [0·27–0·84]; p=0·0092). 
Serious adverse events were reported by 76 (34%) of 222 patients in the chemotherapy plus placebo 
group and 69 (31%) of 226 in the chemotherapy plus erlotinib group. The most common grade 3 or 
greater adverse events were neutropenia (65 [29%] patients and 55 [25%], respectively), 
thrombocytopenia (32 [14%] and 31 [14%], respectively), and anaemia (26 [12%] and 21 [9%], 
respectively). 
 
Conclusion 
Intercalated chemotherapy and erlotinib is a viable first-line option for patients with non-small-cell lung 
cancer with EGFR mutation-positive disease or selected patients with unknown EGFR mutation status. 
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Nintedanib (Vargatef®) for the second-line therapy of advanced or 
recurrent NSCLC 
Drug description: an oral triple angiokinase inhibitor 
Incidence in Austria: 4,200 patients, about 85% of all lung cancers belong to NSCLC 
EMA/FDA licensing: -/- 
 
Phase III results: 
 
Reck et al. Docetaxel plus nintedanib vs. docetaxel plus placebo in patients with previously treated 
NSCLC (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet 2014; 15 (2): 
143-155. 
 
Background 
The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as 
secondline therapy for non-small-cell lung cancer (NSCLC). 
 
Methods 
Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-
line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, 
histology, and presence of brain metastases, were allocated (by computer-generated sequence 
through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m² by intravenous 
infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2–21, 
every 3 weeks until unacceptable adverse events or disease progression. Investigators and patients 
were masked to assignment.The primary endpoint was PFS by independent central review, analysed 
by intention to treat after 714 events in all patients. The key secondary endpoint was overall survival, 
analysed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in 
patients with adenocarcinoma who progressed within 9 months after start of first-line therapy, then in 
all patients with adenocarcinoma, then in all patients. 
 
Results 
Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel 
plus nintedanib and 659 to receive docetaxel plus placebo. The primary analysis was done after a 
median follow-up of 7·1 months (IQR 3·8–11·0). PFS was significantly improved in the docetaxel plus 
nintedanib group compared with the docetaxel plus placebo group (median 3·4 months [95% CI 2·9–
3·9] vs 2·7 months [2·6–2·8]; hazard ratio [HR] 0·79 [95% CI 0·68–0·92], p=0·0019). After a median 
follow-up of 31·7 months (IQR 27·8–36·1), overall survival was significantly improved for patients with 
adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the 
docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo 
group (199 patients; median 10·9 months [95% CI 8·5–12·6] vs 7·9 months [6·7–9·1]; HR 0·75 [95% 
CI 0·60–0·92], p=0·0073). Similar results were noted for all patients with adenocarcinoma histology 
(322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; 
median overall survival 12·6 months [95% CI 10·6–15·1] vs 10·3 months [95% CI 8·6–12·2]; HR 0·83 
[95% CI 0·70–0·99], p=0·0359), but not in the total study population (median 10·1 months [95% CI 
8·8–11·2] vs 9·1 months [8·4–10·4]; HR 0·94, 95% CI 0·83–1·05, p=0·2720). Grade 3 or worse 
adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel 
plus placebo group were diarrhoea (43 [6·6%] of 652 vs 17 [2·6%] of 655), reversible increases in 
alanine aminotransferase (51 [7·8%] vs six [0·9%]). 35 patients in the docetaxel plus nintedanib group 
and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease 
progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one 
with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and 
pulmonary embolism (none vs three). 
 
Conclusion 
Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced 
NSCLC previously treated with one line of platinum-based therapy, especially for patients with 
adenocarcinoma. 
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Colorectal Cancer 
Bevacizumab (Avastin®) as maintenance therapy for patients with 
advanced colorectal carcinoma 
Drug description:  an iv., anti-VEGF monoclonal antibody consisting of humanized murine 
antibody with antigen-binding, complementary-determining regions from murine VEGF 
Incidence in Austria: metastatic colorectal cancer: 2,230 
EMA/FDA licensing: -/January 2013: FDA approval for bevacizumab for use in combination with 
fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for the treatment of 
patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first-line 
bevacizumab-containing regimen. 
Phase III results:  
 
Bennouna et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer 
(ML18147): a randomised phase 3 trial. Lancet 2013;14: 29–37 
 
Background 
Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and 
bevacizumab-naive second-line metastatic colorectal cancer. We assessed continued use of 
bevacizumab plus standard second-line chemotherapy in patients with metastatic colorectal cancer 
progressing after standard first-line bevacizumab-based treatment. 
 
Methods 
In an open-label, phase 3 study in 220 centres in Austria, Belgium, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, the Netherlands, Norway, Portugal, Saudi Arabia, Spain, Sweden, 
and Switzerland, patients (aged ≥18 years) with unresectable, histologically confirmed metastatic 
colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus 
chemotherapy were randomly assigned in a 1:1 ratio to second-line chemotherapy with or without 
bevacizumab 2·5 mg/kg per week equivalent (either 5 mg/kg every 2 weeks or 7·5 mg/kg every 3 
weeks, intravenously). The choice between oxaliplatin-based or irinotecan-based second-line 
chemotherapy depended on the first-line regimen (switch of chemotherapy). A combination of a 
permuted block design and the Pocock and Simon minimisation algorithm was used for the 
randomisation. The primary endpoint was overall survival, analysed by intention to treat. This trial is 
registered with ClinicalTrials.gov, number NCT00700102. 
 
Results 
Between Feb 1, 2006, and June 9, 2010, 409 (50%) patients were assigned to bevacizumab plus 
chemotherapy and 411 (50%) to chemotherapy alone. Median follow-up was 11·1 months (IQR 6·4–
15·6) in the bevacizumab plus chemotherapy group and 9·6 months (5·4–13·9) in the chemotherapy 
alone group. Median overall survival was 11·2 months (95% CI 10·4–12·2) for bevacizumab plus 
chemotherapy and 9·8 months (8·9–10·7) for chemotherapy alone (hazard ratio 0·81, 95% CI 0·69–
0·94; unstratified log-rank test p=0·0062). Grade 3–5 bleeding or haemorrhage (eight [2%] vs one 
[<1%]), gastrointestinal perforation (seven [2%] vs three [<1%]), and venous thromboembolisms (19 
[5%] vs 12 [3%]) were more common in the bevacizumab plus chemotherapy group than in the 
chemotherapy alone group. The most frequently reported grade 3–5 adverse events were neutropenia 
(65 [16%] in the bevacizumab and chemotherapy group vs 52 [13%] in the chemotherapy alone 
group), diarrhoea (40 [10%] vs 34 [8%], respectively), and asthenia (23 [6%] vs 17 [4%], respectively). 
Treatment-related deaths were reported for four patients in the bevacizumab plus chemotherapy group 
and three in the chemotherapy alone group. 
 
Conclusion 
Maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond 
disease progression has clinical benefits in patients with metastatic colorectal cancer. This approach is 
also being investigated in other tumours, including metastatic breast and non-small cell lung cancers. 
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Chronic lymphocytic leukaemia 
Obinutuzumab afutuzumab (Gazyva®) as first line therapy for 
chronic lymphocytic leukaemia  
Drug description: A glycoengineered, fully humanized IgG1 monoclonal antibody with potential 
antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to 
the extracellular domain of the human CD20 antigen on malignant human B cells. iv administration.  
 Incidence in Austria: ~ 350 patients newly diagnosed/year 
EMA/FDA licensing status: -/November 2013: FDA approved obinutuzumab for use in 
combination with chlorambucil for the treatment of patients with previously untreated CLL. 
Phase III results:  
 
Goede et al. Obinutuzumab plus Chlorambucil in patients with CLL and coexisting conditions. 
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. The New England 
journal of medicine. 2014; 370(12):1101-10. 
 
Background 
The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been 
shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic 
leukemia (CLL) but not in those with coexisting conditions. We investigated the benefit of the type 2, 
glycoengineered antibody obinutuzumab (also known as GA101) as compared with that of rituximab, 
each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions. 
 
Methods 
We randomly assigned 781 patients with previously untreated CLL and a score higher than 6 on the 
Cumulative Illness Rating Scale (CIRS) (range, 0 to 56, with higher scores indicating worse health 
status) or an estimated creatinine clearance of 30 to 69 ml per minute to receive chlorambucil, 
obinutuzumab plus chlorambucil, or rituximab plus chlorambucil. The primary end point was 
investigator-assessed progression-free survival. 
 
Results 
The patients had a median age of 73 years, creatinine clearance of 62 ml per minute, and CIRS score 
of 8 at baseline. Treatment with obinutuzumab–chlorambucil or rituximab–chlorambucil, as compared 
with chlorambucil monotherapy, increased response rates and prolonged progression-free survival 
(median progression-free survival, 26.7 months with obinutuzumab–chlorambucil vs. 11.1 months with 
chlorambucil alone; hazard ratio for progression or death, 0.18; 95% confidence interval [CI], 0.13 to 
0.24; P<0.001; and 16.3 months with rituximab–chlorambucil vs. 11.1 months with chlorambucil alone; 
hazard ratio, 0.44; 95% CI, 0.34 to 0.57; P<0.001). Treatment with obinutuzumab–chlorambucil, as 
compared with chlorambucil alone, prolonged overall survival (hazard ratio for death, 0.41; 95% CI, 
0.23 to 0.74; P = 0.002). Treatment with obinutuzumab–chlorambucil, as compared with rituximab–
chlorambucil, resulted in prolongation of progression-free survival (hazard ratio, 0.39; 95% CI, 0.31 to 
0.49; P<0.001) and higher rates of complete response (20.7% vs. 7.0%) and molecular response. 
Infusion-related reactions and neutropenia were more common with obinutuzumab–chlorambucil than 
with rituximab–chlorambucil, but the risk of infection was not increased. 
 
Conclusion 
Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and 
coexisting conditions. In this patient population, obinutuzumab was superior to rituximab when each 
was combined with chlorambucil. 
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Idelalisib (GS-1101) for relapsed chronic lymphocytic leukaemia 
Drug description: an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase 
Incidence in Austria: ~ 350 CLL patients newly diagnosed/year  
EMA/FDA licensing approval status: -/- 
Phase III results:  
 
Furman RR, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England 
journal of medicine. 2014;370(11):997-1007. 
 
Background 
Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting 
medical conditions are less able to undergo standard chemotherapy. Effective therapies with 
acceptable side-effect profiles are needed for this patient population. 
 
Methods 
In this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the 
efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in 
combination with rituximab versus rituximab plus placebo. We randomly assigned 220 patients with 
decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to 
receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily. The primary end 
point was progression-free survival. At the first prespecified interim analysis, the study was stopped 
early on the recommendation of the data and safety monitoring board owing to overwhelming efficacy. 
 
Results 
The median progression-free survival was 5.5 months in the placebo group and was not reached in 
the idelalisib group (hazard ratio for progression or death in the idelalisib group, 0.15; P<0.001). 
Patients receiving idelalisib versus those receiving placebo had improved rates of overall response 
(81% vs. 13%; odds ratio, 29.92; P<0.001) and overall survival at 12 months (92% vs. 80%; hazard 
ratio for death, 0.28; P = 0.02). Serious adverse events occurred in 40% of the patients receiving 
idelalisib and rituximab and in 35% of those receiving placebo and rituximab. 
 
Conclusion 
The combination of idelalisib and rituximab, as compared with placebo and rituximab, significantly 
improved progression-free survival, response rate, and overall survival among patients with relapsed 
CLL who were less able to undergo chemotherapy. 
 
Thyroid cancer 
Cabozantinib (Cometriq®) in patients with unresectable, locally 
advanced or metastatic medullary thyroid cancer (MTC) 
 
Drug description: a potent dual inhibitor of the MET and VEGF pathways designed to block MET 
driven tumor escape, oral administration 
Incidence in Austria: ~ 70 patients 
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EMA/FDA licensing: -/11/2012: approval of cabozantinib for the treatment of patients with 
progressive metastatic MTC 
Phase III results:  
Elisei et al.Cabozantinib in progressive medullary thyroid cancer. Official journal of the American 
Society of Clinical Oncology. 2013;31(29):3639-46. 
 
Purpose 
Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular 
endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical 
activity in patients with medullary thyroid cancer (MTC) in phase I. 
 
Patients and Methods 
We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with 
documented radiographic progression of metastatic MTC. Patients were randomly assigned (2:1) to 
cabozantinib (140 mg per day) or placebo. The primary end point was progression-free survival (PFS). 
Additional outcome measures included tumor response rate, overall survival and safety. 
 
Results 
The estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo (hazard 
ratio, 0.28; 95% CI, 0.19 to 0.40; P <.001). Prolonged PFS with cabozantinib was observed across all 
subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic). 
Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of 
RET mutation status. Kaplan-Meier estimates of patients alive and progression-free at 1 year are 
47.3% for cabozantinib and 7.2% for placebo. Common cabozantinibassociated adverse events 
included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and 
fatigue and resulted in dose reductions in 79% and holds in 65% of patients. Adverse events led to 
treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated 
patients. 
 
Conclusion 
Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with 
progressive metastatic MTC and represents an important new treatment option for patients with this 
rare disease. This dose of cabozantinib was associated with significant but manageable toxicity. 
 
Mantle cell carcinoma 
Ibrutinib (Imbruvica®) in patients with relapsed or refractory mantle 
cell lymphoma  
 
Drug description: covalently binds to, and irreversibly inhibits, Bruton’s Tyrosine Kinase (BTK), 
resulting in the inhibition of B-cell proliferation and survival as well as inhibition of B-cell migration 
and homing. oral administration 
 
Incidence in Austria: ~50 – 100 patients/year 
EMA/FDA licensing: -/November 2013: FDA approved ibrutinib for Mantle cell lymphoma (MCL) 
who have received at least one prior therapy 
Phase III results: None 
 
